medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Integrating anamnestic and lifestyle data with sphingolipids levels for risk-based prostate cancer screening

Caterina Peraldo-Neia[a§], Paola Ostano[a§], Melissa Savioli[a], Maurizia Mello-Grand[a], Ilaria Gregnanin[a], Francesca Guana[a], Francesca Crivelli[b], Francesco Montagnani[b], Michele Dei-Cas[c], Rita Paroni[c], Antonella Sinopoli[d], Francesco Ferranti[d], Nicolò Testino[d], Marco Oderda[e], Andrea Zitella[e], Chiara Fiameni[e], Amedeo Gagliardi[f,g], Alessio Naccarati[f,g], Luca Clivio[h], Paolo Gontero[e], Stefano Zaramella[d] and Giovanna Chiorino[a]*

a. Genomics Lab, Fondazione Edo ed Elvo Tempia, 13900 Biella, Italy

b. Clinical Research Division, Ospedale degli Infermi, 13875 Ponderano (BI), Italy

c. Department of Health Sciences, University of Milan, 20142 Milano, Italy

d. Department of Urology, Ospedale degli Infermi, 13875 Ponderano (BI), Italy

e. Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Torino, Italy

f. Italian Institute for Genomic Medicine, Candiolo Institute, 10060 Candiolo (TO), Italy

g. Candiolo Cancer Institute, FPO IRCCS, 10060 Candiolo (TO), Italy

h. Unit of Analytics, Research & Communication - Area ICT, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.

§ these authors equally contributed

* Corresponding author: tel +39 015 351830 4 1; fax +39 015 21116; email giovanna.chiorino@fondazionetempia.org

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Abstract

Background: In the new era of risk-based prostate cancer (PCa) screening, stratifying men by their individual risk is crucial. Our study aims to integrate anamnestic, life-style and molecular data to minimize unnecessary second-level investigations (SLI) and improve detection of clinically significant PCa (ISUP>1).

Methods: Since 2021, within the DP3 study, we collected plasma samples, recent clinical history, familiarity for cancer, and life-style information from: 421 men who underwent PSA testing and digital rectal examination (longitudinal sampling every 6 months), 421 men with suspected PCa, before diagnostic biopsy and 62 men with PCa diagnosis, before radical prostatectomy. Fifty sphingolipids were tested in the plasma of 393 men by targeted lipidomics. Univariable logistic regression analysis was applied to identify the variables associated with PCa. Multivariable penalized logistic regression analysis with 10-fold cross validation was run on different subgroups of the total cohort to build each time 10 models on 9/10 of the samples and assess their performance on the 10 test sets.

Results: PSA levels, age, cardiovascular diseases (CVD), number of medications, hypertension, sedentariness, and three sphingolipids (Gb3.24, Cer.20, Cer.24.1) showed a significant association with clinically significant PCa in univariable analysis of the entire cohort. Penalized logistic regression modelling consistently selected hypertension, CVD, PSA, age and five sphingolipids (HexCer.20, Cer.20, HexCer.24.1, GM3.24.1, DHCer.24) as key variables to accurately classify PCa (average ROC AUC on the 10 test sets: 0.92 vs 0.85 for PSA). In men recalled for SLI, PSA showed poor discriminatory ability, but PSA, age, CVD, SM.16, HexCer.20, HexCer.24.1, DHS1P, and DHCer.24 were consistently selected by 10/10 models (average ROC AUC: 0.83 vs 0.65 for PSA). Cer.20 and CVD or CVD alone were key variables also for the discrimination of ISUP>1 PCa within the entire cohort or within men recalled for SLI, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Conclusions: The evaluation of individual risk factors and circulating sphingolipids may allow for a more accurate identification of PCa in the context of tailored screening.

Keywords: Prostate cancer detection; second level investigations; life-style; circulating sphingolipids; personalized screening; clinical history

Introduction

Prostate cancer (PCa) is the most commonly diagnosed cancer and ranks as the fifth leading cause of cancer-related deaths among men in Italy and Austria (https://gco.iarc.who.int/en; Globocan 2022, version 1.1). Digital rectal examination (DRE) has low sensitivity in identifying PCa (1). Measuring ematic prostate-specific antigen (PSA) levels enables early PCa detection, but presents some limitations: aggressive tumors can be missed in men with PSA levels below 4 ng/ml and higher PSA levels do not automatically correspond to a PCa diagnosis. This last aspect leads to the significant downside of unnecessary invasive biopsies for a large fraction of men (2). Multiparametric magnetic resonance imaging (MRI) offers high accuracy in detecting clinically significant PCa and can reduce the need for unnecessary biopsies. However, it is resource-intensive, requiring experienced radiologists, considerable time, and significant costs. A set of biomarkers able to complement PSA and DRE in the identification of patients who require further clinical examinations is mandatory to spare patients without PCa from unpleasant, costly, and invasive procedures.

Starting from the analysis of plasma samples collected before diagnostic biopsy from nearly 400 men, we previously reported two circulating microRNAs associated with PCa, especially when PSA was lower than 4 ng/ml (3). In parallel, we uncovered a possible role of ceramides in discriminating PCa from benign prostatic hyperplasia (BPH) when PSA was in the so-called “grey zone”, with 40% reduction of PSA false positives (4). Ceramides are structurally defined as sphingoid bases, typically

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

sphingosine with 18 carbons, attached to a fatty acyl chain of variable length (14 to 26 carbons), the most common one being 16 carbons in mammalian cells (5). Ceramides are essential intermediates in the biosynthesis and metabolism of all sphingolipids and regulate many pathways, such as apoptosis, cell cycle, cell senescence and differentiation, through the synthesis and degradation of different sphingolipids (6). Their homeostasis is crucial and their role in regulating biological processes is still partly unexplored, with some species associated with a tumor suppression and other to a tumor promoting function (7). Interestingly, aberrations in circulating species of the sphingolipid pathways have been consistently found in patients with localized PCa that clinically progressed or with metastatic/castration therapy resistant PCa (8–10), in PCa resistant to docetaxel (11) or to androgen receptor signalling inhibitors (12), as well as in neuroendocrine PCa (13) and in prostate cells treated with fatty acid synthase inhibitor, highlighting a role also in mediation of lipid damage (14).

Recent advancements in metabolomic profiling have evidenced a dysregulation of amino acids and sphingolipid metabolism during the development of PCa (15). Case-control studies from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (16–18) have highlighted patterns of circulating metabolites, including sphingolipids, associated with PCa cancer risk or with the development of aggressive PCa. However, to our knowledge no study has yet exploited samples from men undergoing longitudinal PCa screening or diagnostic biopsy to measure such molecules, alone or in combination with PSA and individual risk factors.

In this work, we took advantage of a prospective collection of plasma samples and questionnaire records from men undergoing organized PSA testing and DRE, prostate biopsy for suspected PCa, or radical prostatectomy. Information on lifestyle, cancer familiarity and comorbidities was analyzed in association with PCa diagnosis, to highlight the most important risk factors. We then combined them with PSA, and circulating sphingolipid levels to create models to better identify men who need SLIs

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

and discriminate those who harbor intermediate and high grade PCa (International Society of Urological Pathology – ISUP – higher than 1) from the others.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Material and methods

Cohort recruitment, sample and data collection

421 men (age range: 50-69) undergoing organized PSA screening at Fondazione Edo ed Elvo Tempia (FEET) were prospectively recruited between September 2021 and October 2023. Blood sampling was carried out at recruitment and every six months, for at least three times. All the recruited subjects were checked by a urologist and underwent DRE. Those recalled for SLI were followed-up according to the European Association of Urology (EAU) guidelines (https://uroweb.org/guidelines/prostate-cancer). Sixty-two PCa patients were prospectively recruited at the Biella Hospital (BH) between October 2022 and April 2024. Blood sampling was carried out before surgery and at each follow-up, according to the EAU guidelines. 421 men were prospectively recruited at Molinette Hospital (MH) before diagnostic biopsy for suspected PCa, and blood sampling was carried out at recruitment. Subjects with negative DRE and no alteration of PSA for at least 4 consecutive evaluations were named healthy donors, “HD”; these, together with subjects with negative MRI/biopsy, were named “nonPCa”.

Self-reported questionnaires on lifestyle (physical activity, body mass index (BMI), diet, smoke and alcohol consumption), familiarity, past prostate biopsies and concurrent pathologies, as well as PSA levels and DRE outcomes, have been collected for each subject recruited at FEET, BH and MH. An online password protected database (https://www.keyform.eu) was used to upload the electronic Case Report Forms (eCRF) including questionnaires, urological visit report, PSA dosage and lab analyses at each follow-up, as well as histological and clinical information for PCa. Information on selected records can be downloaded to carry out statistical analyses. Each patient was pseudoanonymized and signed an informed consent.

The observational clinical protocol called DP3 coordinated by FEET was approved by the Novara ethical committee (AOU Maggiore della Carità) in September 2020 (Prot. N° 968/CE 07/09/2020, integration Prot. N°263/CE, 10/03/2021), in accordance with the Declaration of Helsinki Ethical

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Principles for Medical Research involving Human Participants. The MH ethical committee (AOU Città della Salute e della Scienza) in Turin approved the DP3 study in January 2022 (Prot. N° 521/2021, 10/01/2022).

A summary of the cohorts available is depicted in **Table 1**.

Table 1: site distribution of patients/samples available, tumor characteristics and analyses performed. CVD: cardiovascular disease.

Sites	FEET	BH	MH	total
Total recruited (Blood sampling at enrolment – Plasma isolation and storage – PSA – DRE)	421	62	421	**904**
Blood sampling every 6 months for at least 4 times	408	na	na	**408**
Blood sampling after surgery for at least 4 times	13	62	na	**75**
Questionnaire filled	421	62	421	**904**
Complete data for PSA, age, hypertension, CVD, sedentariness, medications	417	60	337	**814**
Targeted sphingolipid analysis	182	56	155	**393**
SLI performed	40	62	421	**523**
PCa diagnosed	13	62	260	**335**
ISUP > 1	6	56	234	**296**

Blood sample processing

Whole blood was collected in 3 EDTA K2 tubes (10 ml each, D.P. MEDICAL s.r.l., Centallo (TO), Italy) by venipuncture. Plasma was isolated within 1 hour from blood sampling. FEET and BH samples were processed at the Genomics Lab of FEET while MH samples were processed at MH. For plasma separation, tubes were centrifuged at 2500 rpm for 10 min at 4°C; supernatant was then collected in new 15 ml tubes and centrifuged at 2500 rpm for 10 min at 4°C again; plasma was then aliquoted in barcoded tubes and stored at -80°C. Frozen plasma samples from MH were then sent to the Genomics Lab of FEET.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

PSA evaluation

PSA concentration was centrally evaluated at BH for all the men recruited at FEET and BH using Elecsys total PSA kit IVD (Cobas, Roche Diagnostics, Monza, Italy). For the men recruited at MH, pre-biopsy PSA records were shared with FEET, according to the study protocol and the data transfer agreement.

Targeted sphingolipid analysis and processing

Frozen plasma aliquots were sent to the Department of Health Sciences, University of Milan, where 50 species of the sphingolipid metabolism (Ceramides, dihydroCeramides, sphingomyelins, hexosylCeramides, lactosylCeramides, globotriaosylCeramides, gangliosides GM3, sphingosines – see complete list in **Supplementary table 1**) have been analyzed in a subset of 393 plasma samples by mass spectrometry. Briefly, from 25 μL of plasma, sphingolipids were isolated by monophasic extraction (methanol/chloroform 2:1, Merk Life Science S.r.l., Milan, Italy) coupled to alkaline methanolysis. The extracts were resuspended in pure methanol and injected in a LC-MS/MS apparatus: Dionex 3000 UPLC, (ThermoFisher Scientific, Monza, (MB), Italy), coupled to 3200 QTRAP, (AB Sciex S.r.l. Milan, Italy). The chromatographic separation was attained on a C8 column for complex sphingolipids and a C18 column for sphingoid bases.

Four species were undetectable in most of the samples and 46 sphingolipids were retained for the analysis. Z-score standardization was performed on raw data, and batch effect was corrected using the ComBat function from the *sva* package in R.

Lifestyle score calculation

A lifestyle score reflecting concordance with the World Cancer Research Fund (WCRF) Recommendations (19) and the indications of the Italian Guidelines for a healthy diet (20) was defined. Starting from questionnaire data available, five parameters were considered: BMI, physical activity, dietary habits, smoking habit and alcohol consumption. A value between -1 and +1, based

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

on a lesser or greater adherence to the WCRF Recommendations and the indications of the Italian Guidelines, was assigned to each parameter, as detailed below. For BMI score, the value of 1 was given to each subject whose BMI was in the range of healthy weight (18.5-24.9), 0.5 for underweight (< 18.5), 0 for overweight (25.0-29.9), -1 for obesity (≥ 30). For physical activity, self-reported engagement in high level physical activity (3 or more times a week) was assigned a value of 1, moderate physical activity (1-2 times a week) a value of 0, while sedentariness a value of -1. For smoking, 1 was assigned to those subjects who reported not smoking or quitting more than 15 years ago, 0 to those who had quit less than 15 years prior and -1 to current smokers. For alcohol, 1 was given for no consumption, 0.5 was given for alcohol consumption frequency of 1-2 times a week, 0 for a frequency of 3-4 times a week and -1 for a daily alcohol consumption. For diet, the definition of a score was more complex because of the variety of food items and the requirement to assess the overall dietary pattern of each subject. Calculation details are reported in the supplementary materials.

Statistical analyses

The Shapiro-Wilk normality test was applied to continuous variables in order to test the normality of their distributions. Log transformation was applied when the normality assumption was not satisfied. Univariable and multivariable logistic regression analysis were applied to identify features associated with PCa diagnosis. Least absolute shrinkage and selection operator (LASSO) penalized logistic regression, with 10-fold cross-validation, was applied to retrieve the variables associated with PCa in 10/10 penalized regression models. The performance of the 10 models on the test sets was compared with the performance of PSA alone or of the multivariable models combining PSA and age.

The area under the Receiver Operator Curve (ROC AUC) was calculated to assess the discriminatory ability of the variables or models, with reported 95% confidence intervals (C.I.), or range when the 10 AUCs were averaged. Paired DeLong test was used to compare the discrimination among different variables/models. Youden index was used as the criterion to derive a cut-off point on the predicted probabilities and compute true/false positives/negatives, sensitivity and specificity.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Wilcoxon and Chi-square tests were applied to compare continuous and categorical covariates between groups, respectively.

All analyses were performed using the *glmnet*, *pROC*, *ggpubr*, and *stats* packages within the statistical computing environment R (version 4.2.1). Associations were considered statistically significant if the p-value of the univariable logistic regression analysis was below 0.001. Differences were considered statistically significant if the p-value of the Wilcoxon, Chi-square or DeLong tests were below 0.01.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Results

Sample characteristics

In total, baseline plasma samples were available from 904 men in the DP3 cohorts (FEET+BH+MH) (**Table 1**). Within the MH cohort, 260 out of 421 subjects (61.8%) had a positive biopsy. Within the FEET cohort, 13 out of 40 subjects who underwent SLI were classified as PCa (32.5%): of them, three are under active surveillance (AS), one was treated with radiotherapy (RT), three had prostatectomy in other hospitals than BH, six were surgically treated at BH and were followed-up like the 62 PCa patients enrolled before surgery at BH. The clinical, lifestyle and demographic characteristics of the men enrolled in the DP3 study who filled the questionnaire on life-style habits, anamnestic information and risk factors are reported in **Table 2**.

Table 2: characteristics of the men enrolled who filled the questionnaire on lifestyle habits, anamnestic information and risk factors. Wilcoxon or Fisher exact tests were carried out according to the type of variable analyzed.

	Entire cohort	Non-PCa	PCa	P-value
Age (median, range), n=902	64.7 (43.2-88.9)	61.7 (48.96-82.6)	69.7 (43.2-88.9)	<0.00001
PSA (median, range), n=903	4.363 (0.02-1000)	1.96 (0.02-39.4)	7 (0.5-1000)	<0.00001
Familiarity, cancer (%), n=837	53.4	52.6	54.9	0.5662
Familiarity, PCa (%), n=823	12.6	11.3	15.2	0.1367
Cardiovascular diseases (%), n=875	13.6	9.1	21.5	<0.00001
Diabetes (%), n=882	8.05	6.4	10.9	0.0259
Hypertension (%), n=881	44.6	37.97	56.3	<0.00001
Medications (%), n=880	67.3	60.4	79.4	<0.00001
BMI (median, range), n=832	25.6 (14.9-48.2)	25.4 (14.9-48.2)	26.1 (19.3-37.0)	0.0439
Sedentariness (%), n=833	26.9	22.9	34.4	0.000497
Smoke[1] (%), n=848	25.6	26.3	24.3	0.5906
Alcohol[2] (%), n=833	71.7	75.3	64.8	0.0018

[1] smoker or previous smoker who quit less than 15 years before enrolment; [2] consumers, with any frequency.

The study workflow is depicted in **Figure 1**.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.



Results

PCa vs nonPCa

- PSA **AUC 0.85**
- PSA+age+CVD+hypertension **AUC 0.89**

- PSA **AUC 0.85**
- PSA+age+CVD+hypertension+ 5 sphingolipids (DHCer.24, HexCer.20, HexCer.24.1, Cer.20, GM3.24.1) **AUC 0.92**

ISUP>1 vs ISUP=1+nonPCa

- PSA **AUC 0.85**
- PSA+CVD **AUC 0.89**

- PSA **AUC 0.84**
- PSA+age+CVD+ 1 sphingolipid (Cer20) **AUC 0.90**

SLI - PCa vs nonPCA

- PSA **AUC 0.65**
- PSA+age+CVD+5 sphingolipids (DHCer.24, HexCer.20, HexCer.24.1, DHS1P, SM.16) **AUC 0.83**

SLI - ISUP>1 vs ISUP=1+nonPCa

- PSA **AUC 0.60**
- PSA+age+CVD **AUC 0.70**

217

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 1: Workflow of the study. FEET: Fondazione Edo ed Elvo Tempia; BH: Biella Hospital; MH: Molinette Hospital; SLI: Second level investigation; HD: Healthy donors. CVD: cardiovascular diseases; BMI: Body Mass Index. Black dashed borders: men recalled for SLI. Red rectangulars: PCa. Green rectangulars: non PCa

Lifestyle and risk factors

All the 904 enrolled men within the DP3 cohorts received a questionnaire on lifestyle, familiarity, past biopsies and concurrent pathologies. The analysis of questionnaires revealed that age, pharmacological treatments in general, hypertension, cardiovascular diseases (CVD) and sedentariness were significantly associated with PCa, independently of PSA. Age, CVD and the number of medications were positively associated also with ISUP>1 PCa when ISUP1 tumors were included in the reference group, independently of PSA (**Table 3**).

Table 3: Odds ratios (OR) and p-values of the indicated variables analyzed with univariable or multivariable (with PSA adjustment) logistic regression analysis on the DP3 cohort. Med = number of medications; hypert = hypertension; CVD = cardiovascular disease; sedent = sedentariness; diab = diabetes.

Entire DP3 cohort								
	Univariable analysis (any PCa)		PSA adjustment (any PCa)		Univariable analysis (ISUP>1)		With PSA adjustment (ISUP>1)	
	OR	P-value	OR	P-value	OR	P-value	OR	P-value
PSA	1.27	**<0.0001**				**<0.0001**		
age	1.14	**<0.0001**	1.09	**<0.0001**	1.15	**<0.0001**	1.11	**<0.0001**
med	1.24	**<0.0001**	1.16	**0.00014**	1.22	**<0.0001**	1.15	**0.0005**
hypert	2.10	**<0.0001**	1.56	0.0102	2.02	**<0.001**	1.47	0.0279
CVD	2.73	**<0.0001**	2.86	**<0.0001**	3.02	**<0.0001**	3.35	**<0.0001**
sedent	0.57	**0.0004**	0.79	0.233	0.60	0.0020	0.86	0.438
Only men recalled for SLI								
	Univariable analysis (any PCa)		PSA adjustment (any PCa)		Univariable analysis (ISUP>1)		With PSA adjustment (ISUP>1)	
	OR	P-value	OR	P-value	OR	P-value	OR	P-value
PSA	1.05	0.0071			1.06	**0.0008**		
age	1.06	**<0.0001**	1.06	**<0.0001**	1.07	**<0.0001**	1.07	**<0.0001**
med	1.03	0.4476	1.05	0.2471	1.03	0.3997	1.05	0.1919
hypert	1.33	0.1273	1.29	0.1839	1.28	0.1759	1.24	0.2533
CVD	1.86	0.0179	2.07	0.0066	2.17	0.0021	2.53	**0.00037**
sedent	0.85	0.4482	0.86	0.4906	0.91	0.6244	0.92	0.6984

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Sedentary men had substantially higher recall rates than those who usually undertake moderate/high-level physical activity (p-value < 0.00001) and PSA was significantly lower in men used to regular physical activity (p-value < 0.001) compared to the others. The final diet score was negatively associated with PCa, but with low statistical significance (OR=0.80; p-value=0.035). As expected, PSA was significantly associated with PCa in the entire prospective cohort (**Table 3**), with an ROC AUC of 0.84 (C.I: = 0.82-0.87) (**Figure 2A**). Combination of age with PSA improved the discrimination (DeLong p-value = 0.0002), with an AUC of 0.87 (C.I. = 0.85-0.89) (**Figure 2A**).



Figure 2: ROC curves for the identification of PCa of any ISUP grade: PSA (red) and the logistic regression model that combines PSA and age (orange) for 904 patients (A) and for the subgroup of patients who underwent SLI (B). ROC curve for the identification of PCa of ISUP>1 among patients who underwent SLI (C): PSA (red) and the logistic regression

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

model that combines PSA, age and CVD (blue). AUCs and their confidence intervals are reported, as well as the p-values of the DeLong test between curve pairs.

To test whether a model including the clinical covariates with significant association to PCa could improve the discriminatory ability of PSA and age, we considered the subset with complete information on PSA, age, hypertension, CVD, sedentariness and the number of medications (n=814). We applied penalized LASSO logistic regression modelling with 10-fold cross-validation and obtained 10 models, that were tested each time on the 1/10 of samples not used for model construction. The average ROC AUC on the 10 test sets was 0.89 (range: 0.84-0.93), while for PSA it was 0.85 (range: 0.81-0.91). PSA, age, hypertension and CVD were selected by 10/10 models and sedentariness by 9/10, indicating their relevance for the identification of men who really need SLI and for the implementation of targeted prevention actions.

When the same analysis was conducted including ISUP1 PCa in the reference set, we obtained an average ROC AUC on the 10 test sets of 0.89 (range: 0.83-0.94), while for PSA it was 0.85 (range: 0.79-0.94). Age and CVD were selected by 10/10 models, hypertension by 9/10, sedentariness by 6/10.

When we considered only the men who underwent SLI (n=523), the ROC AUC of PSA dropped to 0.59 (C.I. = 0.54-0.64) showing minimal predictive potential (**Figure 2B**). No covariate except PSA and age resulted associated with PCa in this subgroup in univariable and multivariable analysis. Instead, CVD was significantly associated with ISUP>1 PCa in multivariable analysis (p-value < 0.001) and with slightly lower significance in univariable analysis (p-value = 0.0021) (**Table 2**). The combination between age and PSA improved the discrimination of PCa of any ISUP grade from the rest, compared to PSA alone (DeLong p-value = 0.0091), and the inclusion of CVD allowed for a better identification of ISUP>1 PCa (DeLong p-value < 0.001). However, ROC AUCs were still poor (**Figure 2B-C**), indicating the need of stronger predictors.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Targeted sphingolipid analysis

Leveraging our previous findings on ceramide-like metabolites useful for the discrimination of PCa when PSA is in the so called grey-zone (4), we decided to perform targeted sphingolipid analysis. Fifty sphingolipids, including ceramides, dihydro-ceramides, hexosyl-ceramides, sphingomyelins, dihydro-sphingosine, sphingosine and its phosphorylated form, were analyzed on plasma samples using LC-MS/MS. All these molecules are characterized by an 18-carbon sphingoid base but harbor variable number of carbons in the fatty acids, ranging from 14 to 24. 46 sphingolipids were detected in all samples and were retained for the analysis.

Gb3.24, Cer.20, and Cer.24.1 were significantly associated with PCa of any grade and with ISUP>1 PCa, in univariable analysis on the samples of the DP3 cohorts.

LASSO regression modelling with 10-fold cross-validation was applied to the subset of men with complete information on circulating molecules, lifestyle and clinical data (n=369). The average ROC AUC of the 10 models in the test sets was 0.92 (range: 0.84-0.99), compared to 0.85 (range: 0.76-0.93) and 0.88 (range: 0.80-0.98) for PSA alone and PSA combined with age, respectively (**Figure 3A**). Hypertension, CVD, PSA, age and five sphingolipids (HexCer.20 and Cer.20 with positive coefficients; HexCer.24.1, GM3.24.1, DHCer.24 with negative coefficient) were selected in 10/10 models. PSA, age, CVD and Cer.20 were selected in 10/10 models also when the predicted outcome was ISUP>1 PCa. **Figure 3B** shows the predicted probabilities of harboring ISUP>1 PCa given by the multivariable models built using PSA, age, CVD and Cer.20, with predicted probabilities increasing with increasing ISUP grade. In **Figure 3C**, the samples are ordered by the predicted probabilities from one of the 10 models, which includes PSA, age, CVD, hypertension and 10 sphingolipids. Some ISUP >1 PCa cases (red dots) appear below the horizontal dashed line on the right side of the figure, indicating patients with high predicted probabilities despite low PSA levels.

The same approach was applied considering only the men who underwent SLI (n=221). In this case, only CVD, PSA and age together with five sphingolipids were selected by 10/10 models. Namely,

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

SM.16 and HexCer.20 had positive coefficients, while HexCer.24.1, DHS1P, and DHCer.24 had negative coefficients. The improvement in the average ROC AUC of the 10 models on the 10 test sets not used for model construction was even better, from 0.65 (range: 0.56-0.83) and 0.70 (range: 0.56-0.87) for PSA and PSA combined with age, respectively, to 0.83 (range: 0.57-0.92) for the model including CVD and sphingolipids (**Figure 3D**).



Figure 3: (A) Classification performances of the multivariable models vs PSA alone in the entire cohort with complete information on sphingolipids and lifestyle/clinical variables. (B) Predicted probabilities of harboring a PCa of ISUP grade >1 given by the multivariable model built using or PSA, age, CVD and Cer.20. (C) Representation of logPSA, logAge, sphingolipid levels, hypertension and CVD state in each subject, ordered by the predicted probabilities of harboring an ISUP>1 PCa. Grey dots correspond to nonPCa, orange to ISUP1 PCa and red to ISUP>1 PCa. (D) Classification performances of the multivariable models vs PSA alone in the subgroup of men who underwent SLI.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Discussion

With the implementation of PCa screening policies across European countries, such as PRAISE-U (21), there will be an exponential rise in PSA testing. While this increase enhances early detection, it also raises the risk of dispensable second-level investigations (SLI), which can lead to over diagnosis, patient anxiety, and potential complications from invasive procedures like biopsies (22). To optimize screening benefits and minimize harm, it is crucial to apply risk-stratified approaches and follow evidence-based guidelines to ensure that only high-risk individuals undergo further diagnostic assessments.

In this work, we summarized the results of a prospective multicentre study addressed to men undergoing PSA testing and digital rectal examination, sometimes followed by SLI (MRI and/or prostate biopsy), for the early detection of PCa. The study also included men candidate to prostatectomy. The goal was to improve PSA diagnostic accuracy and reduce unnecessary MRIs/biopsies by integrating lifestyle, age, comorbidity, and easily measured blood markers, ultimately informing targeted prevention strategies.

PSA dosage remains the milestone for PCa detection, even if with its limitations. However, the predictive value of PSA is drastically reduced in those men with PCa suspicion, candidates for SLI; in this subgroup of subjects, only about 60% really have a confirmed PCa diagnosis, actually making necessary the identification of other complementary biomarkers.

One of the findings of our study is that a sedentary lifestyle and cardiovascular diseases (CVD) increase the likelihood of a PCa diagnosis. The association between CVD and PCa should not be considered in the same way that smoking is a risk factor for lung cancer, as both CVD and PCa share some common risk factors, such as age, diet, obesity and lack of exercise. However, a recent study highlighted a causative association between angina pectoris and PCa (23). We also found that combining sedentariness and CVD, along with PSA and age, improves patient selection for SLI. However, the key finding of our research is that analysis of plasma sphingolipids further enhances

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

the precision in detecting PCa among men recalled for suspected PCa (average AUC 0.83). These results are comparable to risk calculators using MRI data (24) (AUC 0.81-0.87 for clinically significant PCa) and significantly better than models without MRI data (2) (AUC 0.66-0.79).

While pre-biopsy MRI in suspected PCa can help over 30% of men avoid immediate biopsy and improve cancer detection – identifying about 15% more clinically significant and 40% fewer clinically insignificant cancers (25) – it also increases the demand for MRI equipment, highly trained staff, manpower and (future) AI-based image analysis. Using a pre-MRI risk assessment tool in a clinical cohort could eliminate over a third of prostate MRIs (or biopsies, if MRI is unavailable) (26), with even greater potential in screening populations where the overall risk of PCa is much lower. Therefore, MRI should be prioritized for men at intermediate and high risk based on a reliable stratification tool (27). The drawback is a potential risk of missing some clinically significant PCas in men considered low-risk (26). In our cohort, the combination of clinical/demographic and laboratory covariates allowed the correct classification of ISUP>1 PCa also in some men with very low serum PSA levels.

The variables most strongly associated with PCa at enrolment were PSA levels, age, number of medications, hypertension, CVD, and sedentariness. Notably, sedentariness is a modifiable risk factor that can influence the other variables. Our observation of decreased PSA levels proportional to exercise frequency in a subgroup of sedentary men participating in a biweekly Nordic-walking program within the DP3 study (manuscript in preparation) further underscores this point. Exercise impacts overall health, including cardiovascular health, and can even influence biological age (28). These findings highlight the critical importance of stratifying patients for PCa screening and implementing risk-adapted strategies. By considering modifiable risk factors like sedentariness, alongside established factors such as PSA and age, we can more effectively identify individuals who would benefit most from further investigation, reducing unnecessary interventions in lower-risk individuals while ensuring timely diagnosis and treatment for those at higher risk. Critically, risk-

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

adapted strategies could include the prescription of targeted exercise programs for sedentary men, addressing a key modifiable risk factor and potentially impacting both PSA levels and overall health.

Interest in circulating sphingolipids as cancer biomarkers has grown rapidly in recent years due to their role as not just structural components of cell membranes, but also active molecules involved in various cellular processes, including cell growth, differentiation, and death. Most of the previous studies on sphingolipids and PCa regard patients with existing PCa diagnoses and have identified sphingolipid signatures associated with cancer progression and therapy resistance (8–13). A prognostic blood-based sphingolipid panel has recently been proposed for men with localized PCa on active surveillance. This panel aims to identify patients at high risk of biopsy Gleason grade upgrading (29). To our knowledge, no blood-based sphingolipid panel exists for the early detection of PCa within a screening context, nor as a pre-MRI/biopsy risk assessment tool for men with suspected PCa.

As part of the abovementioned ancillary study within the DP3 project, we investigated the impact of a 6-month biweekly Nordic-Walking program (led by certified instructors) on quality of life, lifestyle, mobility parameters and circulating molecules in a subgroup of sedentary men enrolled in our study. Interestingly, DHCer24, which was negatively associated with PCa in all multivariable models, after six months proportionally increased with the frequency of activity (manuscript in preparation).

A limitation of this study is the lack of completeness regarding the different levels of information available for the subjects enrolled. We maximized the use of available data without imputing missing values. In multivariable modelling, we used a 10-fold cross-validation approach on each subset analyzed, to avoid overfitting and identify the most robust variables. We plan in the future to extend our analyses on wider datasets as well as to integrate plasma proteomic and urinary microbiome data to identify additional potential biomarkers and provide a more comprehensive understanding.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Conclusion

This study investigated the potential of combining readily available clinical data (PSA, age, hypertension, CVD, sedentariness) with novel circulating biomarkers for improved PCa detection. The research identified specific sphingolipid panels that, when combined with clinical factors, demonstrated strong diagnostic potential for both PCa screening and pre-MRI/biopsy risk assessment. These findings suggest that incorporating sphingolipid analysis could enhance PCa early detection and reduce dispensable invasive procedures.

Future research will expand the analysis to include plasma proteomic and urinary microbiome data for an even more comprehensive understanding and identification of additional biomarkers.

DECLARATIONS

Ethics approval and consent to participate: The observational clinical protocol called DP3 coordinated by FEET was approved by the Novara ethical committee (AOU Maggiore della Carità) in September 2020 (Prot. N° 968/CE 07/09/2020, integration Prot. N°263/CE, 10/03/2021), in accordance with the Declaration of Helsinki Ethical Principles for Medical Research involving Human Participants. The MH ethical committee (AOU Città della Salute e della Scienza) in Turin approved the DP3 study in January 2022 (Prot. N° 521/2021, 10/01/2022).

Consent for publication

NA

Availability of data and materials

Upon reasonable request to the corresponding author.

Competing interests: The authors declare that they have no competing interests

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Funding

The DP3 study was funded by Compagnia di San Paolo (CP-N; FG); Rete Oncologica del Piemonte e della Valle d'Aosta; the National Plan for Complementary Investments to the NRRP, project "D34H—Digital Driven Diagnostics, prognostics and therapeutics for sustainable Health care" (project code: PNC0000001), Spoke 4 financed by the Italian Ministry of University and Research (MS); Fondazione CRT (CP-N; MM-G; PO; IG; GC).

Authors' contributions (da adattare): CPN: Conceptualization, Methodology, Investigation, Resources, Data Curation, Writing - Review & Editing. **PO**: Conceptualization, Software, Validation, Formal analysis, Data Curation, Writing - Review & Editing, Visualization. **MS**: Formal analysis, Investigation, Resources, Data Curation, Visualization. **MMG**: Conceptualization, Investigation, Resources, Writing - Review & Editing. **IG**: Investigation, Resources. **FG**: Software, Writing - Review & Editing. **FC**: Resources. **FM**: Resources. **MDC**: Investigation. **RP**: Supervision. **AS**: Resources. **FF**: Resources. **NT**: Resources. **MO**: Conceptualization, Resources, Writing - Review & Editing. **AZ**: Conceptualization, Resources. **CF**: Resources, Data Curation. **AG**: Resources. **AN**: Funding acquisition, Writing - Review & Editing. **LC**: Data Curation. **PG**: Resources, Supervision. **SZ**: Resources, Supervision. **GC**: conceptualization, methodology, Writing - Original Draft and Review & Editing, Supervision, Project Administration and Funding acquisition.

All authors read and approved the final manuscript

Acknowledgements

We thank all patients who agreed to participate in the DP3 study, as well as all the nurses, physicians and students supporting sample collection and processing.

Authors' information (optional)

References

1. Matsukawa A, Yanagisawa T, Bekku K, Kardoust Parizi M, Laukhtina E, Klemm J, et al. Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology. agosto 2024;7(4):697–704.

2. Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. maggio 2015;26(5):848–64.

3. Mello-Grand M, Gregnanin I, Sacchetto L, Ostano P, Zitella A, Bottoni G, et al. Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. Carcinogenesis. 29 aprile 2019;40(2):246–53.

4. Mello-Grand M, Bruno A, Sacchetto L, Cristoni S, Gregnanin I, Dematteis A, et al. Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA. Front Oncol. 19 novembre 2021;11:769158.

5. Pal P, Atilla-Gokcumen GE, Frasor J. Emerging Roles of Ceramides in Breast Cancer Biology and Therapy. IJMS. 23 settembre 2022;23(19):11178.

6. Hannun YA, Obeid LM. Author Correction: Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. ottobre 2018;19(10):673.

7. Petrusca DN, Lee KP, Galson DL. Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets. Front Oncol. 8 giugno 2022;12:925807.

8. Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, et al. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. settembre 2021;24(3):860–70.

9. Cattrini C, Manfredi M, Barboro P, Ghirimoldi M, Mennitto A, Martini V, et al. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 18 ottobre 2023;13(1):17791.

10. Scheinberg T, Lin HM, Fitzpatrick M, Azad AA, Bonnitcha P, Davies A, et al. PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. Prostate Cancer Prostatic Dis. marzo 2024;27(1):136–43.

11. Finnerty MC, Leach FE, Zakharia Y, Nepple KG, Bartlett MG, Henry MD, et al. Identification of blood lipid markers of docetaxel treatment in prostate cancer patients. Sci Rep. 27 settembre 2024;14(1):22069.

12. Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. eBioMedicine. ottobre 2021;72:103625.

13. Lee C, Chen Y, Hernandez E, Pong R, Ma S, Hofstad M, et al. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC. Clinical & Translational Med [Internet]. febbraio 2022 [citato 28 febbraio 2023];12(2). Disponibile su: https://onlinelibrary.wiley.com/doi/10.1002/ctm2.695

14. Ribeiro CF, Rodrigues S, Bastos DC, Fanelli GN, Pakula H, Foiani M, et al. Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition. Sci Signal. 9 aprile 2024;17(831):eadh1922.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

15. Lin X, Lécuyer L, Liu X, Triba MN, Deschasaux-Tanguy M, Demidem A, et al. Plasma Metabolomics for Discovery of Early Metabolic Markers of Prostate Cancer Based on Ultra-High-Performance Liquid Chromatography-High Resolution Mass Spectrometry. Cancers (Basel). 23 giugno 2021;13(13):3140.

16. Breeur M, Ferrari P, Dossus L, Jenab M, Johansson M, Rinaldi S, et al. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition. BMC Med. 19 ottobre 2022;20(1):351.

17. Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition. BMC Med. dicembre 2017;15(1):122.

18. Schmidt JA, Fensom GK, Rinaldi S, Scalbert A, Appleby PN, Achaintre D, et al. Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPIC. Int J Cancer. febbraio 2020;146(3):720–30.

19. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Recommendations and public health and policy implications. Available at dietandcancerreport.org.

20. Rossi L, Berni Canani S, Censi L, Gennaro L, Leclercq C, Scognamiglio U, et al. The 2018 Revision of Italian Dietary Guidelines: Development Process, Novelties, Main Recommendations, and Policy Implications. Front Nutr. 25 marzo 2022;9:861526.

21. Chandran A, Van Harten M, Singh D, Vilaseca J, Patasius A, Tupikowski K, et al. Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project. European Urology Open Science. dicembre 2024;70:8–17.

22. Osama S, Serboiu C, Taciuc IA, Angelescu E, Petcu C, Priporeanu TA, et al. Current Approach to Complications and Difficulties during Transrectal Ultrasound-Guided Prostate Biopsies. J Clin Med. 16 gennaio 2024;13(2):487.

23. Bai T, Wu C. Association of cardiovascular disease on cancer: observational and mendelian randomization analyses. Sci Rep. 24 dicembre 2024;14(1):28465.

24. Mortezavi A, Palsdottir T, Eklund M, Chellappa V, Murugan SK, Saba K, et al. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. Eur Urol Focus. maggio 2021;7(3):546–53.

25. Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 25 aprile 2019;4(4):CD012663.

26. Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, et al. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. Eur Urol Oncol. giugno 2018;1(2):109–17.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

27. Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. agosto 2017;72(2):250–66.

28. Nagata M, Komaki S, Nishida Y, Ohmomo H, Hara M, Tanaka K, et al. Influence of physical activity on the epigenetic clock: evidence from a Japanese cross-sectional study. Clin Epigenetics. 15 ottobre 2024;16(1):142.

29. Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, et al. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res. 9 novembre 2024;12(1):134.

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Supplementary materials

Lifestyle score calculations

The reported weekly consumption frequencies ("never", "once", "2-3 times", "more than 3 times") for each food in the questionnaire were therefore assessed, in particular: "Pasta", "Rice", "White bread", "Wholegrain bread", "White meat", "Red meat", "Fish", "Fried food", "Cereals", "Legumes", "Fruit", "Vegetables", "Sweets", "Eggs", "Diary products". To each food or combination of foods, a value between -1 and +1 was given according to the consumption frequencies recommended by the Italian Guidelines and the WCRF Recommendations. By adding the values attributed, an overall score for nutrition was calculated, ranging from 0 to 14.5, where higher scores indicated more adequate dietary habits, while lower scores an unhealthy diet. This score was further categorized into 5 classes: class 1 (0≤score≤7), class 2 (7<score≤8.75), class 3 (8.75<score≤10), class 4 (10<score≤11.5), class 5 (11.5<score≤14.5). Finally, the five scores thus created for BMI, physical activity, smoke, alcohol and diet were summed to obtain the final lifestyle score: higher lifestyle scores reflected a healthier global lifestyle, while lower scores were associated with worse lifestyle habits, predisposing to an increased risk of many pathologies.

Supplementary Table 1: List of sphingolipids analysed.

CERAMIDES	**GANGLIOSIDES GM3**
Cer.14	GM3.16
Cer.16	GM3.18
Cer.18:1	GM3.18:1
Cer.18	GM3.20
Cer.20	GM3.22
Cer.22	GM3.24:1
Cer.24:1	GM3.24
Cer.24	**GLOBOTRIAOSYLCERAMIDES**
DIHYDROCERAMIDES	Gb3.16
DHCer.16	Gb3.18
DHCer.18:1	Gb3.18:1
DHCer.18	Gb3.20
DHCer.24:1	Gb3.22
DHCer24	Gb3.24
HEXOSYLCERAMIDES	Gb3.24:1
HexCer.16	**SPHINGOSINES**
HexCer.18:1	Sph
HexCer.18	S1P
HexCer.20	DHSph
HexCer.22	DHS1P
HexCer.24:1	**SPHINGOMYELINS**
HexCer.24	SM.16
LACTOSYLCERAMIDES	SM.18:1
LacCer.16	SM.18
LacCer.18:1	SM.24:1
LacCer.18	SM.24
LacCer.20	
LacCer.22	
LacCer.24:1	
LacCer.24	

medRxiv preprint doi: https://doi.org/10.1101/2025.03.07.25323552; this version posted March 10, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.